Taux de survie à 5 ans sur la période 2000-2016, par groupe diagnostique et tranche d'âge - RNCE

Registre National des Cancers de l’Enfant

5-year overall survival rates of childhood cancer in mainland France over 2000-2016, by diagnostic and age groups.

                 
                   
 

< 1 year

1-4 years

5-9 years

10-14 years

 

Diagnostic groups and subgroups

I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases

61.2

[56.6-65.5]

89.9

[88.8-90.8]

89.2

[87.9-90.4]

80.8

[78.8-82.5]

**

I.a Lymphoid leukemias

53.8

[46.4-60.7]

93.8

[92.9-94.6]

91.4

[90.1-92.6]

84.0

[81.9-86]

**

I.b Acute myeloid leukemias

66.1

[58.9-72.4]

66.9

[61.9-71.3]

80.8

[75.6-85.1]

67.6

[62.4-72.3]

**

II. Lymphomas and reticuloendothelial neoplasms

92.9

[59.1-99.0]

92.5

[89.3-94.8]

94.4

[92.7-95.7]

94.7

[93.5-95.6]

 

II.a Hodgkin lymphomas

-

-

100.0

-

98.6

[96.3-99.5]

97.4

[96.3-98.2]

 

II.b Non-Hodgkin lymphomas (except Burkitt lymphomas)

90.9

[50.8-98.7]

86.4

[79.9-90.9]

89.9

[85.9-92.7]

90.3

[87.2-92.7]

 

II.c Burkitt lymphomas

100.0

-

96.0

[91.8-98.1]

95.1

[92.3-96.9]

90.4

[85.6-93.6]

 

III. CNS and miscellaneous intracranial and intraspinal neoplasms

62.7

[58.2-66.9]

72.9

[71-74.6]

72.4

[70.6-74.2]

81.4

[79.7-83.1]

**

III.a Ependymomas and choroid plexus tumors

70.5

[60.3-78.5]

67.9

[62.1-72.9]

79.9

[72.2-85.6]

86.9

[79.7-91.6]

**

III.b Astrocytomas

82.5

[75.1-87.8]

94.3

[92.6-95.5]

82.9

[80.3-85.3]

82.5

[79.4-85.1]

**

III.c Intracranial and intraspinal embryonal tumors

26.1

[18.7-34.1]

38.1

[33.8-42.3]

69.1

[64.6-73.1]

79.1

[73.3-83.8]

**

III.d Other gliomas

67.2

[50.3-79.5]

44.5

[38.2-50.5]

26.2

[22.0-30.6]

47.0

[41.3-52.6]

**

III.e Other specified intracranial and intraspinal neoplasms

84.2

[71.9-91.5]

94.2

[90.5-96.5]

95.6

[93.2-97.1]

96.7

[94.9-97.8]

**

IV. Neuroblastomas and other peripheral nervous cell tumors

90.7

[88.6-92.4]

67.2

[64.3-70.0]

66.1

[59.7-71.8]

71.4

[60.0-80.0]

**

IV.a Neuroblastomas and ganglioneuroblastomas

90.7

[88.7-92.5]

67.1

[64.2-69.9]

66.2

[59.7-71.9]

62.8

[49.4-73.6]

**

V. Retinoblastomas

99.5

[97.9-99.9]

99.0

[97.5-99.6]

100.0

-

100.0

-

 

VI. Renal tumors

88.3

[83.5-91.9]

94.3

[92.7-95.6]

93.2

[89.8-95.5]

81.9

[70.3-89.3]

**

VI.a Nephroblastomas and other nonepithelial renal tumors

88.3

[83.5-91.9]

94.3

[92.7-95.6]

93.3

[89.8-95.6]

85.0

[69.6-93.0]

**

VII. Hepatic tumors

89.9

[80.8-94.8]

87.3

[80.8-91.7]

74.4

[55.0-86.4]

62.4

[45.5-75.4]

**

VII.a Hepatoblastomas

89.7

[80.5-94.7]

87.5

[80.8-91.9]

74.6

[51.9-87.7]

44.4

[13.6-71.9]

**

VIII. Malignant bone tumors

85.7

[33.4-97.9]

74.2

[63.2-82.4]

75.2

[70.5-79.2]

73.6

[70.5-76.4]

 

VIII.a Osteosarcomas

100.0

-

57.1

[28.4-78.0]

71.1

[63.4-77.4]

71.7

[67.2-75.7]

 

VIII.c Ewing tumors and related bone sarcomas

80.0

[20.4-96.9]

78.4

[65.6-86.9]

77.4

[70.7-82.7]

73.9

[68.9-78.2]

 

IX. Soft tissue and other extraosseous sarcomas

69.8

[62.9-75.8]

75.2

[71.4-78.5]

75.3

[71.2-78.9]

68.2

[64.1-72.0]

**

IX.a Rhabdomyosarcomas

84.6

[73.3-91.4]

76.3

[71.9-80.0]

72.9

[67.5-77.6]

60.8

[53.1-67.6]

**

IX.b Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms

88.7

[76.5-94.7]

91.7

[53.9-98.8]

82.6

[60.0-93.1]

67.2

[50.7-79.3]

 

IX.d Other specified soft tissue sarcomas

39.0

[26.7-51.1]

72.7

[63.0-80.3]

79.2

[71.3-85.2]

72.6

[66.8-77.6]

**

IX.e Unspecified soft tissue sarcomas

56.3

[29.5-76.2]

49.7

[27.4-68.5]

74.5

[56.4-85.9]

71.0

[57.8-80.7]

 

X. Germ-cell tumors, trophoblastic tumors, and neoplasms of gonads

91.3

[87.1-94.2]

96.3

[92.7-98.1]

96.9

[92.6-98.7]

93.5

[90.7-95.4]

*

X.a Intracranial and intraspinal germ cell tumors

91.6

[76.1-97.2]

93.4

[84.8-97.2]

95.6

[88.6-98.3]

94.5

[90.3-96.9]

 

X.b Malignant extracranial and extragonadal germ cell tumors

89.1

[83.5-92.9]

96.2

[88.6-98.8]

100.0

-

85.7

[66.1-94.4]

 

X.c Malignant gonadal germ cell tumors

100.0

-

100.0

-

100.0

-

96.0

[92.1-98.0]

 

XI. Other malignant epithelial neoplasms and malignant melanomas

96.9

[79.8-99.6]

87.5

[79.0-92.7]

93.1

[88.6-95.8]

94.0

[91.8-95.6]

 

XI.b Thyroid carcinomas

100.0

-

100.0

-

98.8

[91.5-99.8]

98.9

[96.6-99.6]

 

XI.d Malignant melanomas

100.0

-

81.0

[62.5-91.0]

89.3

[76.2-95.4]

88.3

[79.9-93.4]

 

XII. Other and unspecified malignant neoplasms

100.0

-

76.5

[58.4-87.5]

85.7

[33.4-97.9]

58.6

[26.7-80.6]

 

All cancers (excluding Langherhans cell histiocytosis)

81.3

[79.9-82.7]

83.3

[82.6-84.1]

82.6

[81.7-83.4]

83.7

[82.9-84.5]

**

Langherhans cell histiocytosis

87.2

[73.8-94.1]

96.4

[86.2-99.1]

100.0

-

100.0

-

 

All cancers (including Langherhans cell histiocytosis)

81.4

[80.0-82.8]

83.4

[82.7-84.1]

82.6

[81.7-83.4]

83.8

[82.9-84.6]

**

                   

** pvalue <0.01; * pvalue < 0.05

                 
                   
                   

Villejuif

INSERM
UMRS1153 Equipe 7
Bâtiment 15/16
16 avenue Paul Vaillant Couturier
94807 Villejuif Cedex

+33 (0)1 45 59 50 37
rnhe@inserm.fr

Nancy

Faculté de Médecine
BP 20199
9 avenue de la Forêt de Haye
54505 Vandoeuvre les Nancy Cedex

+33 (0)3 72 74 63 26
rntse@inserm.fr